Diagnostic Utility of Prolactin in Neuropathology
Immunohistochemical detection of PRL is an established component of the diagnostic evaluation of pituitary neuroendocrine tumors (PitNETs), formerly designated pituitary adenomas.
Anti-PRL antibodies are routinely used for:
- Identification and confirmation of lactotroph PitNETs (prolactinomas).
- Functional classification of pituitary neuroendocrine tumors according to hormone production profiles.
- Characterization of mixed or plurihormonal PitNETs in conjunction with pituitary lineage transcription factors and additional pituitary hormone markers in accordance with contemporary WHO classification criteria.
- Differentiation of prolactin-secreting neoplasms from non-functioning pituitary tumors and other sellar lesions.
- Investigation of exceptionally rare cases of ectopic prolactin production in neuroendocrine neoplasms and other tumors.
Key Features of Prolactin CE/IVD Antibodies
General characteristics commonly reported in CE/IVD instructions for use (IFUs) and technical datasheets include:
- Validation for formalin-fixed paraffin-embedded (FFPE) tissue sections and immunohistochemistry applications.
- Availability in monoclonal antibody formats, including mouse and rabbit-derived clones depending on the manufacturer.
- Predominantly cytoplasmic staining patterns in normal lactotroph cells and prolactin-producing PitNETs.
- Demonstrated reactivity with human pituitary tissue and prolactin-secreting pituitary tumors.
- Availability in both ready-to-use (RTU) and concentrated formulations.
- Compatibility with automated and manual staining platforms.
- Inclusion of CE/IVD-compliant quality control procedures and lot-to-lot validation processes.
